2019/06/28 15:43:23 | |
---|---|
Price | |
1.37 EUR | |
Difference | 2.24% (0.03) |
ISIN | CH0029850754 |
Symbol | ADXN |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 8 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 1.36 EUR |
High | 1.37 EUR |
Low | 1.36 EUR |
Close (prev. day) | 1.34 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 7 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings | ||
2024/07/03 | Global Strategy 3Q 2024 | ||
2024/06/21 | Global Equity Ratings |
2019/06/28 15:43:23 | |
---|---|
Price | |
1.37 EUR | |
Difference | 2.24% (0.03) |
ISIN | CH0029850754 |
Symbol | ADXN |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 8 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 1.36 EUR |
High | 1.37 EUR |
Low | 1.36 EUR |
Close (prev. day) | 1.34 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 7 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -28.83% | -41.70% | -40.87% |
Perf (abs.) | -0.56 | -0.98 | -0.95 |
Beta | 0.45 | 1.06 | 0.83 |
Volatility | 38.91 | 38.02 | 47.39 |
Ø price 5 days | Ø volume 5 days (pcs.) | 1.39 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 1.40 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 1.52 EUR (189) |
Ø price 250 days | Ø volume 250 days (pcs.) | 1.89 EUR (97) |
YTD High | date | 2.10 EUR (2019/01/08) |
YTD Low | date | 1.31 EUR (2019/06/06) |
52 Weeks High | date | 2.44 EUR (2018/09/04) |
52 Weeks Low | date | 1.31 EUR (2019/06/06) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2019/06/28 | 15:43 | 1.37 EUR | 0.00 | 7 |
SIX Swiss Exchange | 2024/09/27 | 09:00 | 0.069 CHF | 0.00 | 2 |
London Stock Exchange | 2024/05/02 | 17:55 | 0.064 CHF | 0.01 | 1 |
Frankfurt | 2019/06/28 | 17:14 | 1.355 EUR | 0.00 | 7 |
Berlin | 2019/06/28 | 15:58 | 1.37 EUR | 0.00 | 5 |
ADDEX THERAPEUTICS LTD. |
- - |
9, Chemin des Mines, Plan-les-Ouates - 1202 Genf |
Telefon: +41-22-884-15-55 |
Fax: +41-22-884-15-56 |
E-mail: info@addextherapeutics.com |
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland. |
Timothy Dyer | Chairman of Managing Board |
Lénaic Teyssédou | Member of Executive Committee |
Mikhail Kalinichev | Member of Executive Committee |
Roger Mills | Member of Executive Committee |
Isaac Manke | Member of the administrative board |
Raymond Hill | Member of the administrative board |
Roger Mills | Member of the administrative board |
Jake Nunn | Member of the administrative board |
Vincent Lawton | Chairman of the administrative boar |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer